Nine Months of Delamanid, Linezolid, Levofloxacin, and Pyrazinamide for the Treatment of Fluoroquinolone-Sensitive Multidrug-Resistant Tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): A Phase II/III, Multicenter, Randomized, Open-Label, Clinical Trial